John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being marketed around the world. He further talks opportunities in the topical pain management market and how Nuvo Pharmaceuticals will enhance its portfolio by acquiring more products, while continuing to bring its own products to various markets around the world.
John, when you and your partners took over management of Nuvo Pharmaceuticals in 2005, the company had no FDA approved product, approximately CAD 50 million (USD 39 million) in debt and two weeks of cash Under your leadership, Nuvo has obtained four FDA approvals and now has over CAD 17 million (USD 13 million) in cash and no debt. What are your secrets to success?
"We are not only interested in global or territorial rights to products that we can in-license or acquire, but want to secure manufacturing rights for those products as well."
